Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib

NCT01871805 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01871805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01871805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2013
Completion date
August 31, 2017
Enrollment
134 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer